Anand Jillella, MD
Chief, Division of Hematology/Oncology
- Augusta GA UNITED STATES
An expert in acute promyelocytic leukemia, Jillella is founding director of the adult stem cell and bone marrow transplant program.
Multimedia
Social
Biography
Jillella’s current research, funded by the Leukemia/Lymphoma Society, is a novel induction therapy for acute promyelocytic leukemia, a cancer of the white blood cells, which dramatically reduces mortality rates and starts as a national ECOG/ACRIN clinical trial. His clinical focus is bone marrow transplantation for leukemia, multiple myeloma and other blood-related malignancies.
Areas of Expertise
Media Appearances
Dr. Anand Jillella receives Georgia CORE’s Optimistic Oncologist Award
Jagwire - Augusta University online
2018-01-12
Dr. Anand Jillella, the J. Harold Harrison, MD, Distinguished University Chair in Medical Oncology at the Medical College of Georgia at Augusta University, is the recipient of the first Optimistic Oncologist Award from the Georgia Center for Oncology Research and Education (Georgia CORE).
Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia
Cancer Currents - National Cancer Institute online
2018-01-03
It’s not often that a cancer clinical trial recruits a handful of oncologists to staff a round-the-clock help desk of sorts for their peers. But that’s the case for a unique NCI-funded trial that is attempting to address a serious problem for patients who have a very rare cancer, acute promyelocytic leukemia (APL).
A national study to cure a specific form of leukemia happening in Augusta
News Channel 6 tv
2017-11-22
Happening right now—a national study to cure a specific form of Leukemia and it is taking place right here in Augusta. News Channel 6’s Ashley Osborne sat down with the program leader and one of his patients.
Jillella returns as J. Harold Harrison MD Chair for Medical Oncology
Jagwire - Augusta University online
2017-05-18
Dr. Anand P. Jillella returns to the Medical College of Georgia at Augusta University July 1 as the J. Harold Harrison, MD, Distinguished University Chair in Medical Oncology.
Articles
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
CancerJee Hyun Kong MD, PhD, Elliott F. Winton MD, Leonard T. Heffner MD, Zhengjia Chen PhD, Amelia A. Langston MD, Brittany Hill PA, Martha Arellano MD, Fuad El-Rassi MD, Audrey Kim RN, Anand Jillella MD, Vamsi K. Kota MD, Imre Bodó MD, PhD, Hanna Jean Khoury MD
2017
To the authors' knowledge, the optimal frequency of monitoring after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML) has not been established.
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib
Clinical Lymphoma, Myeloma & LeukemiaVamsi K. Kota'Correspondence information about the author Vamsi K. KotaEmail the author Vamsi K. Kota, Jee Hyun Kong, Martha Arellano, Fuad El Rassi, Manila Gaddh, Leonard T. Heffner, Elliott F. Winton, Anand P. Jillella, Morgan L. McLemore, H. Jean Khoury (in memoriam)
2017
The second-generation tyrosine kinase inhibitors (TKIs) (2G-TKIs) dasatinib (DAS) and nilotinib (NIL) yield faster responses in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) as compared with imatinib (IM); however, long-term safety of these agents is a growing concern
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
Therapeutic Advances in HematologySikander Ailawadhi, Luke P. Akard, Carole B. Miller, Anand Jillella, Daniel J. DeAngelo, Solveig G. Ericson, Felice Lin, Ghulam Warsi, Jerald Radich
2016
The phase II, exploratory, open-label Exploring Nilotinib BCR-ABL Effects (ENABL) study [ClinicalTrials.gov identifier: NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) who had a suboptimal molecular response with imatinib.